Nevertheless, in cutaneous melanoma also patients with negative PD-L1 status can respond to IT, as shown by a previous study with an ORR of 54% and 72% in patients with negative or positive PD-L1 status, respectively [23]. The gene discussed is CD274; the disease is cutaneous melanoma.